News
Quotient Sciences Invests in Drug Substance Manufacturing Facility
Quotient Sciences, a drug development and manufacturing company, is investing £6.3 million pounds ($8.6mn) in its recently acquired manufacturing facility in Alnwick, UK. The investment will expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over...
Drug Research
Innovent Biologics, Bolt Biotherapeutics Enter Immuno oncology Alliance
Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for cancer, metabolic, autoimmune and other diseases, and Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents, entered a collaboration to research...
News
SK bioscience & GSK initiate phase 3 trial of adjuvanted Covid-19 vaccine candidate
SK bioscience (SK) and GlaxoSmithKline (GSK) announced the initiation of a phase 3 clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim phase 1/2 results.
The randomised, active-controlled global trial will enroll...
News
Abbott introduces single-dose formulation of carbetocin for prevention of postpartum haemorrhage in India
Abbott, the global healthcare company has announced the introduction of a room-temperature-stable, single-dose formulation of carbetocin in India, which is available in convenient vials, to help in the prevention of postpartum haemorrhage (PPH). Abbott’s product is available in the...
News
Drug Substance Freezing and Why It Doesn’t Have To Be a Bottleneck
Drug substance freezing has moved on.
Traditionally it was inefficient in a multitude of ways. Issues such as product loss, reduction of product potency, or a lack of flow with the surrounding processes such bulk filling, storage and shipping were...
News
Rapid Development and Industrialization of a COVID-19 Viral Vector Vaccine Manufacturing Process
The year 2020 will go down in history books as a year that changed the world and helped drug manufacturing to evolve. When the COVID-19 pandemic began at the start of the year, vaccine production was less of an...
News
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia
Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on "Non-clinical and clinical pathways for rapid vaccine development in Australia", in a webinar hosted by Endpoints...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















